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Abstract
Background: Combination drug therapy appears a promising approach to overcome drug resistance and reduce
drug-related toxicities in ovarian cancer treatments. In this in vitro study, we evaluated the antitumor efficacy of
cisplatin in combination with Bithionol (BT) against a panel of ovarian cancer cell lines with special focus on
cisplatin-sensitive and cisplatin-resistant cell lines. The primary objectives of this study are to determine the nature
of the interactions between BT and cisplatin and to understand the mechanism(s) of action of BT-cisplatin
combination.
Methods: The cytotoxic effects of drugs either alone or in combination were evaluated using presto-blue assay.
Cellular reactive oxygen species were measured by flow cytometry. Immunoblot analysis was carried out to
investigate changes in levels of cleaved PARP, XIAP, bcl-2, bcl-xL, p21 and p27. Luminescent and colorimetric assays
were used to test caspases 3/7 and ATX activity.
Results: The efficacy of the BT-cisplatin combination depends upon the cell type and concentrations of cisplatin
and BT. In cisplatin-sensitive cell lines, BT and cisplatin were mostly antagonistic except when used at low
concentrations, where synergy was observed. In contrast, in cisplatin-resistant cells, BT-cisplatin combination
treatment displayed synergistic effects at most of the drug ratios/concentrations. Our results further revealed that
the synergistic interaction was linked to increased reactive oxygen species generation and apoptosis. Enhanced
apoptosis was correlated with loss of pro-survival factors (XIAP, bcl-2, bcl-xL), expression of pro-apoptotic markers
(caspases 3/7, PARP cleavage) and enhanced cell cycle regulators p21 and p27.
Conclusion: In cisplatin-resistant cell lines, BT potentiated cisplatin-induced cytotoxicity at most drug ratios via
enhanced ROS generation and modulation of key regulators of apoptosis. Low doses of BT and cisplatin enhanced
efficiency of cisplatin treatment in all the ovarian cancer cell lines tested. Our results suggest that novel
combinations such as BT and cisplatin might be an attractive therapeutic approach to enhance ovarian cancer
chemosensitivity. Combining low doses of cisplatin with subtherapeutic doses of BT can ultimately lead to the
development of an innovative combination therapy to reduce/prevent the side effects normally occurring when
high doses of cisplatin are administered.
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Background
Drug resistance to currently used chemotherapies is the
fundamental cause of recurrence and poor overall sur-
vival in ovarian cancer patients [1–3]. Between 70 and
80% of ovarian cancer patients show an initial positive
response to the standard treatment (cytoreductive sur-
gery and adjuvant paclitaxel and platinum-based chemo-
therapy); however, most of them will recur [4, 5].
Subsequent treatment with second-line or third-line
agents (after interim non-platinum therapy) results in
less than 33% response rate due to the increase of resist-
ance to these drugs [6–9]. The poor survival rate for
women with platinum-resistant ovarian carcinomas de-
mands alternative treatment strategies.
Platinum-based chemotherapy is still an effective treat-
ment for ovarian cancer in spite of severe side effects and
development of resistance associated with its use [10].
Cis-diamminedichloroplatinum (II) (cisplatin) is a
platinum-based compound that has clinical activity
against a wide array of solid cancers including ovarian, tes-
ticular, bladder, colorectal, lung, and head and neck [11].
DNA-damage response and mitochondrial apoptosis play
a major role in cisplatin’s mode of action [12, 13]. In
addition, cisplatin is known to cause oxidative stress [11]
via generation of superoxide anions and hydroxyl radicals
[14]. Despite consistent initial responses, cisplatin treat-
ment often results in the development of chemo-
resistance, leading to therapeutic failure [10, 11]. The use
of cisplatin is also limited by dose associated toxicity and
side effects. Serious side effects that limit the dose of cis-
platin include neurotoxicity and nephrotoxicity [11, 15].
In order to mitigate the side effects and resistance result-
ing from cisplatin-based chemotherapy, it is essential to
investigate new drugs which are non-toxic and work in al-
ternative/similar pathways to cisplatin, thus providing
additional therapeutic options in ovarian cancer.
In recent years, a number of compounds have been ex-
plored in combination with cisplatin. Some of these in-
clude N-acetylcysteine [16], naltrexone [17], glutathione
ester [18], vitamin E and losartan [19], melatonin [20],
quercetin [21], metformin [22, 23], and rehmannia [24].
However, none of these combinations were successful
for clinical application. In the present study, we investi-
gated the novel combination of cisplatin with Bithionol
[2, 2′-Sulfanediylbis (4, 6-dichlorophenol)] (BT) as an al-
ternate therapeutic strategy. BT is a Food and Drug
Administration-approved antiparasitic agent that has
been safely dosed in humans to be used orally as a
second-line medication for the treatment of helminthic
infections [25]. Previously, we showed that BT exerts
cytotoxic effects on a panel of ovarian cancer cell lines
regardless of their cisplatin sensitivities [26]. BT half
maximal inhibitory concentrations (IC50) observed in
several ovarian cancer cell lines were well below the
reported clinically tolerable levels in humans. Our recent
in vivo study did not demonstrate the anti-tumor poten-
tial of BT (pharmaceutical grade); however, lack of tox-
icity at any of the tested doses and the ability of BT to
induce apoptosis still make BT a promising candidate to
be utilized in therapeutics [27]. To further explore the
anti-tumor potential of BT, it is important to know the
combined effects of BT with standard chemotherapeutic
agent(s) such as cisplatin and paclitaxel. In this study, we
assessed the antitumor efficacy of BT in combination with
cisplatin using a panel of ovarian cancer cell lines such as
OVACAR-3, SKOV-3 (Additional file 1) and the isogenic
ovarian cancer cell lines pairs A2780 (cisplatin-sensitive) /
A2780-CDDP (cisplatin-resistant) and IGROV-1 (cisplatin-
sensitive) / IGROV-1CDDP (cisplatin-resistant). The pri-
mary objectives of this study are to determine the optimal
combination of BT and cisplatin to achieve enhanced cyto-
toxic activity of both drugs and to understand the mecha-
nism(s) of action of BT-cisplatin combination.
BT and cisplatin combinations were evaluated systemat-
ically for drug-ratio dependent interactions in vitro. The
nature of the interactions between BT and cisplatin was
evaluated by three different approaches – (1) sequential
addition of drugs that involves pre-treatment with BT for
24 h followed by cisplatin addition (drugs in non-constant
ratio), (2) simultaneous addition of both drugs in non-
constant ratio and (3) simultaneous addition of drugs in
constant ratio. The combination index was used to evalu-
ate if the interactions are antagonistic, synergistic or
additive.
Cisplatin and other anti-neoplastic agents exhibit cyto-
toxic effects via elevation of intracellular reactive oxygen
species (ROS) that may contribute to their therapeutic
effect. BT was shown to induce apoptosis via cell cycle
regulation, ROS generation, NF-κB inhibition and auto-
taxin (ATX) inhibition. To investigate the molecular
mechanism(s) of action of BT-cisplatin combination in
ovarian cancer cells in vitro, we evaluated ROS gener-
ation, ATX inhibition, induction of apoptosis and ex-
pression of key apoptotic and cell cycle modulators.
Methods
Cell lines and chemicals
Isogenic ovarian cancer cell lines pairs, e.g., A2780 /A2780-
CDDP and IGROV-1/, IGROV-1CDDP were received as a
generous gift from Dr. Brodsky (Brown University, Provi-
dence, RI). The parental cell lines were purchased from
Sigma and made resistant in vitro by continuous stepwise
exposure to cisplatin to produce the corresponding
cisplatin-resistant cell lines. All cell lines were maintained
in DMEM media (Sigma) supplemented with 10% heat-
inactivated FBS (Hyclone), 100 IU penicillin (Mediatech)
and 100 μg/mL streptomycin (Mediatech). All cell lines
were cultured at 37 °C in a humidified atmosphere at 5%
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CO2. The cisplatin-resistant variants A2780-CDDP and
IGROV-1CDDP cells were treated with 3 μM cisplatin
every third passage to maintain cisplatin resistance.
BT and cisplatin (Cis-diamminedichloroplatinum (II))
were purchased from Sigma (St Louis, MO). All primary
antibodies were purchased from Cell Signaling Technolo-
gies, (Danvers, MA). PrestoBlue™ Cell Viability Reagent
and ROS Dye - carboxy-H2DCFDA were purchased from
Invitrogen (Carlsbad, CA).
Cell viability assay
Cell viability after drug(s) treatment was determined by
Presto Blue cell viability reagent (Invitrogen) as descried
previously [26]. In brief, ovarian cancer cell lines (5 × 103
cells/well) were plated into 96-well plates (Corning, Inc.,
Corning, NY) and incubated overnight. Cells were
treated with different concentrations of both drugs ei-
ther alone or in combination and incubated for 48 h. BT
was tested at concentrations ranging from 3.56 μM to
100 μM and cisplatin at concentrations between 1.57
and 200 μM. A minimum of 4–6 h prior to the end of
treatment, presto blue reagent was added and incubated
for 48 h followed by measurement of fluorescence
(540 nm excitation/590 nm emissions). DMSO concen-
tration was corrected to 1% in all wells. All treated cells
were compared against control cells (considered as 100%
viable) treated with 1% DMSO media. Data were
expressed as mean ± SD of triplicate experiments.
In order to determine role of ROS in BT-cisplatin in-
duced cytotoxicity, cell viability assays were performed
in the presence the antioxidant ascorbic acid (AA). Cells
were pretreated with 1 mM AA for 2 h prior to addition
of drugs and further incubated for 48 h. Restoration of
cell viability was analyzed.
Drug combination studies
To assess combination effects of BT with cisplatin, these
drugs were combined in constant and non-constant ra-
tios. In constant ratio combination, BT and cisplatin
were combined at a fixed ratio based on the IC50 values
of the individual drugs (i.e., concentrations causing 30–
50% of cytotoxicity when these agents are used alone).
Subsequently, this drug mixture was serially diluted to
obtain different concentrations of the combination. The
dose ranges selected for combination studies were
3.25 μM to 100 μM for BT and 1.56 μM to 200 μM for
cisplatin. For non-constant ratio combination, BT and
cisplatin were prepared at a series of concentrations that
spans the dose–response curves for both drugs. Each
concentration of BT was mixed with each concentration
of cisplatin, thereby producing a matrix of multiple stock
admixtures, containing both drugs together in solution
at a variety of concentrations and ratios.
The nature of the interaction between BT and cisplatin
was assessed using three different approaches: (1) simul-
taneous treatment with both drugs in non-constant ra-
tio, where cells were treated with both BT and cisplatin
simultaneously combined in a non-constant ratio; (2)
simultaneous treatment with both drugs in constant
drug ratio, where cells were treated with both BT and
cisplatin simultaneously combined in a constant ratio
and (3) pre-treatment with BT followed by addition of
cisplatin in non-constant ratio, where cells were treated
with different concentrations of BT for 24 h after which
BT was removed and cisplatin was added for another
24 h. Here also each concentration of BT pre-treatment
is followed by each concentration of cisplatin thereby
producing a matrix of multiple stock admixtures (non-
constant ratio).
The tumor growth inhibition obtained for BT-cisplatin
combination over a range of concentrations was compared
to that obtained for the individual drugs, and a measure of
the synergy between the two drugs, referred to as the
combination index (CI), was calculated using a median-
effect mathematical algorithm [28]. CalcuSyn (BioSoft)
was used to calculate CI values for drug combinations. A
drug combination is synergistic if its CI value is signifi-
cantly below 1; the combination is additive where the CI
is between 0.9 and 1.0; and the combination is antagonis-
tic as indicated by CI values above 1.0.
Caspase 3/7 assay
Caspase 3/7 activity was measured using Caspase-Glo 3/7
assay kit from Promega, following the manufacturer’s in-
structions. Briefly, 10 × 103 cells were plated per well of
the 96-well plate and treated with BT and cisplatin either
alone or in combination. Following treatment, Caspase-
Glo 3/7 reagent was added and incubated for 30 min. at
room temperature. The luminescence intensity was mea-
sured using a luminometer (luminoskan, Thermo Scien-
tifics). Drug-treated cells were compared against cells
treated with 1% DMSO media (controls). Data were
expressed as mean ± SD of triplicate experiments.
Apoptosis detection via Hoechst staining
NucBlue Live Cell Stain (Hoechst 33342; Invitrogen,
Carlsbad, CA) was used to morphologically assess nu-
clear condensation indicative of apoptosis. This qualita-
tive test was performed as described previously [26, 29].
In brief, cells (1 × 105 cells) were seeded into 12-well
plate and treated with BT and cisplatin either alone or in
combination for 24 h. Following treatment, cells were
washed, stained with Hoechst stain (2 drops/mL of
media) for 15 min. at 25 °C and observed under a fluor-
escent microscope. Representative images were taken
with an inverted microscope (Olympus H4-100, CCD
camera) and 20× objective.
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Apoptosis quantification via TUNEL assay
DNA fragmentation was detected using the TiterTACS®
2 TdT in Situ Colorimetric Apoptosis Detection Kit
(Trevigen, Gaithersburg, MD) following the manufac-
turer’s instructions. Briefly, cells were seeded at a dens-
ity of 3 × 104 cells/well, into 96-well flat bottom plates
and incubated overnight. Cells were treated with BT
and cisplatin either alone or in combination for 24 h.
After treatment with drugs, cells were washed and
fixed. Subsequently, labeled nucleotides were added
and measurements were performed with HRP – HRP
substrate (TACS-Sapphire) system. The absorbance was
measured at 450 nm using a microplate reader, Multis-
kan (Thermo Scientifics).
Estimation of reactive oxygen species (ROS) production
Hydrogen peroxide, hydroxyl radicals and peroxy radicals
were detected via carboxy-H2DCFDA using flow cytome-
try as described previously [26]. Briefly, cells (1 × 106) were
seeded in 100 mm2 culture dishes and treated with BT
and cisplatin either alone or in combination for 24 h. After
treatment, the cells were washed once with PBS, collected
by centrifugation after trypsinization, re-suspended in
fresh PBS and incubated with 5 μM 5,6-carboxy-2′,7′-
dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA,
C400, Invitrogen, Eugene, Oregon, USA) for 30 min at
37 °C. The cells were washed twice with PBS, re-
suspended in an equal volume of PBS and fluorescence
measured with flow cytometry. Data was acquired on a
BD Accuri C6 flow cytometer and analyzed using Accuri
C6 software (BD Immunocytometry-Systems, San Jose,
CA). Twenty thousand cells were analyzed for each sam-
ple. Subsequent cell viability assay with AA pretreatment
was performed.
Western blot analysis
Western blotting was performed to evaluate expression
of key modulators of apoptosis such as cleaved PARP,
XIAP, bcl-2 and bcl-xL. Key cell cycle regulators such as
p21 and p27 were also assessed by western blotting. Cell
seeding, cell lysis and western botting were done as de-
scribed previously [26]. In brief, cells were treated with
BT and cisplatin either alone or in combination. After
treatment for 24 h, cells were harvested and lysed in cell
extraction buffer (Invitrogen, Carlsbad, CA) containing
10 mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA,
1 mM EGTA, 1 mM NaF, 20 mM Na4P2O7, 2 mM
Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% SDS,
0.5% deoxycholate protease inhibitor cocktail and PMSF.
Cell lysates were subjected to western blotting. After
overnight incubation with respective primary antibodies
at 4 °C, and subsequent incubation with appropriate sec-
ondary antibodies (Licor), the proteins on the blots were
detected using a Licor image analyzer.
Autotaxin (ATX) assay
The phosphodiesterase activity of ATX was measured as
described previously [26]. In brief, cells were treated with
BT and cisplatin either alone or in combination. Following
treatment, cell-free supernatants were collected. The con-
centration of ATX was normalized with respect to the cell
mass of samples in each well. To estimate ATX, 100 μL
cell-free culture media were incubated with 100 μL sub-
strate containing p-nitrophenylphosphonate (pNppp) at a
final concentration of 5 mM prepared in 50 mM Tris–
HCl buffer, pH 9.0. After 30 min incubation at 37 °C, the
reaction was stopped by the addition of 100 μL of 0.1 M
NaOH solution. The reaction product was measured by
reading the absorbance at 410 nm. ATX inhibition of
treated cells was calculated as the percentage of ATX ac-
tivity in comparison with untreated cells.
Statistical analysis
Comparisons between cisplatin treated and BT/cisplatin
combination treated groups were performed by Student’s
t–test. The significance level was set at p < 0.05.
Results
BT-cisplatin combination cytotoxicity studies
The objective of the present study is to investigate the ef-
fects of BT-cisplatin combination in ovarian cancer cell
lines with special focus on cisplatin-sensitive and cisplatin-
resistant isogenic pair of cell lines. Cells were exposed to
different concentrations of BT and cisplatin either alone or
in combination. The combination index (CI) value, calcu-
lated according to Chou’s methods [28], was used to deter-
mine the nature of the interaction between BT and
cisplatin. The CI results are shown as a heat map where the
green color indicates synergism (CI value < 1), the yellow
color indicates additive effect (CI = 1) and the red color in-
dicates antagonism (CI > 1). Our previous results have
shown that both BT and cisplatin induced cell death in a
time and dose dependent manner when added alone for
48 h (data not shown). BT-cisplatin combination-induced
cytotoxicity profiles on individual ovarian cancer cell lines
are described below:
A2780 (cisplatin-sensitive) and A2780-CDDP (cisplatin-resistant)
isogenic pair
A2780 When A2780 cells were pretreated with BT
followed by cisplatin addition, there was synergy only at
lower BT (3.25 and 6.25 μM) and cisplatin (1.56–6.25 μM)
concentrations (Fig. 1a). At higher concentrations of
cisplatin, an additive effect was observed but only lower BT
concentrations (3.25–6.25 μM). Higher BT concentrations
were antagonistic to cisplatin action (CI >1; represented as
red). Similarly, when cells were treated with BT and cis-
platin simultaneously, antagonism was observed at most
drugs ratios. Synergistic effect was observed only at lower
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BT (3.25 and 6.25 μM) and cisplatin (1.56–6.25 μM) con-
centrations. As shown in Fig. 1b, combination with BT
(12.5 μM) reduced the cytotoxic potential of cisplatin by 4–
12% at lower cisplatin concentrations (1.56–12.5 μM). At
synergistic drug ratios, combination with 6.25 μM BT en-
hanced cytotoxic potential of cisplatin by 4 to 33% at lower
cisplatin concentrations (1.56–12.5 μM). In summary, BT
and cisplatin were in general antagonistic irrespective of the
drug sequence employed. However, synergy was observed
only at lower BT and cisplatin concentrations, when added
simultaneously or when pretreated with BT.
A2780-CDDP In contrast to A2780 (cisplatin-sensitive),
in A2780-CDDP (cisplatin-resistant), BT was synergistic
to cisplatin action at most of the drug ratios either when
cells were pre-treated with BT or when both BT and cis-
platin were added simultaneously (Fig. 1c). At higher BT
concentrations, additive effect was observed. When
added simultaneously, at synergistic drug ratios, combin-
ation with 12.5 μM BT enhanced cytotoxic potential of
cisplatin by 66 to 86% at cisplatin concentrations of
1.56–50 μM (Fig. 1d). The synergistic action of BT and
cisplatin on cisplatin-resistant cell lines was independent
of the drug sequence employed.
IGROV-1 (cisplatin-sensitive) and IGROV-1-CDDP (cisplatin-
resistant) isogenic pair
IGROV-1 When IGROV-1 cells were pretreated with
BT followed by cisplatin addition, antagonism was
observed at most drugs ratios (Fig. 2a). Synergy only
occurred at higher cisplatin (100–200 μM) concentra-
tions, which has no physiological significance. Simi-
larly, when these cells were treated with BT and
cisplatin simultaneously, BT was synergistic to
Fig. 1 Cytotoxic potential of BT-cisplatin combination on the isogenic pair of ovarian cancer cell lines A2780 (cisplatin-sensitive) and A2780-CDDP
(cisplatin-resistant). After determining viability (PrestoBlue assay) of cells treated with combinations of BT and cisplatin, combination index (CI)
values were calculated and represented as heat maps where a drug combination is synergistic (green color) if CI <0.9; additive (yellow color) if CI
is between 0.9 and 1.0; and antagonistic (red color) if CI >1.0. Combination index values for A2780 and A2780-CDDP are shown in (a) and (C)
respectively. Percent cytotoxicity induced by BT/cisplatin combination at synergistic ratios for A2780 (b) and A2780-CDDP (d) are shown in bar
graphs. Comparisons between cisplatin alone-treated and combination-treated for each cell line were performed by Student’s t-test. All data were
expressed as mean ± SD of triplicate experiments. The significance level was set at p < 0.05 as indicated by asterisk (*)
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cisplatin action only at the lowest BT (3.25 μM) and
cisplatin concentrations ranging 1.56 to 12.5 μM. At
higher concentrations of cisplatin, an additive effect
was observed but only at lowest BT concentration
(3.25 μM). Higher BT concentrations were antagonis-
tic to cisplatin action. As shown in Fig. 2b, combin-
ation with BT (50 μM) reduced the cytotoxic
potential of cisplatin by 6–14% at lower cisplatin con-
centrations (1.56–25 μM). At synergistic drug ratios,
combination with 3.25 μM BT enhanced cytotoxic po-
tential of cisplatin by 2 to 26% at lower cisplatin con-
centrations (1.56–12.5 μM). In summary, the actions
of BT and cisplatin on IGROV-1 cells were, in gen-
eral, antagonistic. However, some synergy was ob-
served at lowest BT and cisplatin concentrations only
when pretreated with BT.
IGROV-1-CDDP Interestingly, in the IGROV-1-CDDP
(cisplatin-resistant) cell line, BT was synergistic to cisplatin
action in a drug concentration dependent manner, either
when cells were pre-treated with BT or when both BT and
cisplatin were added simultaneously. Synergy was observed
at low (3.25 μM) or towards higher (50 and 100 μM) con-
centrations of BT when combined with cisplatin at all con-
centrations (Fig. 2c). When added simultaneously, at
synergistic drug ratios, combination with 50 μM BT en-
hanced the cytotoxic potential of cisplatin by 36 to 80% at
cisplatin concentrations of 1.56–25 μM (Fig. 2d).
OVCAR-3 and SKOV-3 In these cell lines, BT and cis-
platin act in general antagonistic, however, synergy was
observed at very narrow drugs ratios with slightly better
Fig. 2 Cytotoxic potential of BT-cisplatin combination on the isogenic pair of ovarian cancer cell lines IGROV-1 (cisplatin-sensitive) and IGROV-1-
CDDP (cisplatin-resistant). After determining viability (via PrestoBlue assay) of cells treated with combinations of BT and cisplatin, combination
index (CI) values were calculated and represented as heat maps where a drug combination is synergistic (green color) if CI <0.9; additive (yellow
color) if CI is between 0.9 and 1.0; and antagonistic (red color) if CI >1.0. a and c show CI values for IGROV-1 and IGROV-1-CDDP respectively.
Percent cytotoxicity induced by BT/cisplatin combination at synergistic ratios for IGROV-1 (b) and IGROV-1-CDDP (d) are shown in bar graphs.
Comparisons between cisplatin alone-treated and combination-treated for each cell line were performed by Student’s t-test. Data were expressed
as mean ± SD of triplicate experiments. Asterisks (*) indicate p < 0.05
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response when both drugs were added simultaneously
(data attached as Additional file 1: Figure S1).
In summary our studies performed using isogenic
pairs of cell lines show that BT and cisplatin are in gen-
eral synergistic in cisplatin-resistant cell lines and antag-
onistic in cisplatin-sensitive cell lines. Synergy was
observed when added simultaneously or when pretreated
with BT. These results further support the fact that BT
sensitizes cisplatin-resistant cells to respond better to
cisplatin treatment.
BT inhibits apoptosis when used in combination with
cisplatin
To determine the mechanisms underlying antagonism or
synergism between BT and cisplatin, we tested the effect
of BT on cisplatin-induced apoptosis in cisplatin-
sensitive and cisplatin-resistant isogenic pairs of cell
lines. Qualitative morphological assessment was per-
formed by nuclear (Hoechst) staining. As shown in
Fig. 3a and c, vehicle-treated (control) cells stained very
faintly while treated cells had a stronger blue fluores-
cence indicative of highly condensed chromatin, charac-
teristic of apoptotic cells. Cisplatin-sensitive cells (A2780
and IGROV-1) treated with either BT or cisplatin alone
showed higher fluorescence than those treated with BT-
cisplatin combination. In contrast, cisplatin-resistant
variants (A2780-CDDP and IGROV-1-CDDP) treated
with BT-cisplatin combination displayed higher fluores-
cence than the same cell lines treated with either BT or
cisplatin alone. Both isogenic pairs of cell lines exhibited
similar profiles. The extent of apoptosis expressed as
percentage of DNA fragmentation was quantified using
the TUNEL assay. As shown in Fig. 3b and d, in both
isogenic cell line pairs, cisplatin-sensitive cell lines
showed considerably higher DNA fragmentation when
treated with cisplatin or BT alone as compared to BT-
cisplatin combination (simultaneous) treatment. A2780
cells treated with 12.5 μM BT or 12.5 μM cisplatin alone
exhibited 17 ± 2 and 28 ± 3% of DNA fragmentation, re-
spectively. When treated with both drugs in combination
(simultaneously or pretreated with BT followed by cis-
platin), the percentage of DNA fragmentation decreased
to 15 ± 1 and 13 ± 1% respectively (Fig. 3b). For A2780-
CDDP cells, treatment with 12.5 μM BT caused 13 ±
2.9% DNA fragmentation. No significant DNA fragmen-
tation was observed when these cisplatin resistant cells
were treated with 12.5 μM cisplatin alone. Upon com-
bination, the percentage of DNA fragmentation in-
creased significantly to 81 ± 3.76 and 75 ± 2%,
respectively, when added simultaneously or pretreated
with BT followed by cisplatin (Fig. 3b). IGROV-1 cells
treated with 50 μM BT or 12.5 μM cisplatin alone
showed 22 ± 2 and 38 ± 3% of DNA fragmentation re-
spectively. When these cells were treated with both
drugs in combination (simultaneously or pretreated
with BT followed by cisplatin), the percentage of
DNA fragmentation decreased to 11 ± 1 and 6 ± 1%
respectively (Fig. 3d). In the case of IGROV-1-CDDP
cells, treatment with 50 μM BT caused 31 ± 2.9%
DNA fragmentation. No significant DNA fragmenta-
tion was observed when these cells where treated
with 12.5 μM cisplatin alone. Upon drug combination,
the percentage of DNA fragmentation increased sig-
nificantly to 61 ± 3.76 and 59 ± 2% respectively, when
drugs were added simultaneously or pretreated with
BT followed by cisplatin (Fig. 3d).
Effect of BT-cisplatin combination on apoptotic markers
In order to confirm the results obtained with DNA frag-
mentation studies, we also assessed other apoptotic
markers. As shown in Fig. 4a and b, significant reduction
of caspases activity was observed when cisplatin-
sensitive variants of isogenic cell line pairs, such as
A2780 and IGROV-1, were treated with BT and cisplatin
in combination, as compared to when treated with either
of the drugs alone. In contrast, cisplatin-resistant vari-
ants of these isogenic cell line pairs (A2780-CDDP and
IGROV1-CDDP) showed increased caspase 3/7 activity
when treated with both drugs in combination as com-
pared to when treated with either of the drugs alone
(Fig. 4a and b).
Similarly, increased PARP protein cleavage product
(85 kDa, 1 fragment) was observed in cisplatin-
sensitive cell lines such as A2780 and IGROV, when
treated with either of the drugs alone (Fig. 4c and d).
However BT-cisplatin combination reduced the ex-
pression of cleaved PARP. In contrast, cisplatin-
resistant variant of these cell lines (A2780-CDDP and
IGROV1-CDDP) showed increased PARP protein
cleavage product when treated with both drugs in
combination as compared to when treated with either
of BT or cisplatin alone.
To confirm that the potentiation/attenuation of
cisplatin-induced cytotoxicity by BT treatment is accom-
panied by changes in the expression of key regulators of
apoptosis, we also assessed the expression of XIAP, bcl-2
and bcl-xL. As shown in Fig. 4c and d, down regulation
of XIAP, Bcl-2, bcl-xL was observed in cisplatin-sensitive
cell lines (A2780 and IGROV-1) when treated with ei-
ther of the drugs alone. However, treating the cells with
BT-cisplatin combination reduced cisplatin-induced
apoptotic effects as the expressions of XIAP, bcl-2 and
bcl-xL increased. In contrast, cisplatin-resistant cell lines
displayed significant down regulation of XIAP, bcl-2,
bcl-xL when treated with BT-cisplatin combination as
compared to either agent alone.
Our results suggest that BT significantly inhibits apop-
tosis when added in combination with cisplatin in
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cisplatin-sensitive cell lines (A2780 and IGROV-1)
whereas it increases apoptosis in cisplatin-resistant vari-
ants (A2780-CDDP and IGROV1-CDDP). Furthermore,
these results suggest that cisplatin in combination with
BT caused down-regulation of key survival proteins such
as XIAP, Bcl-2, and bcl-xL compared to either of the
drugs alone, thus resulting in greater apoptosis/cytotox-
icity. These results show that the nature of drug interac-
tions depends on the extent of apoptosis that occurs
when cells are treated in combination. Synergistic inter-
action enhanced apoptosis whereas antagonistic interac-
tions reduced the extent of apoptosis.
Effect of BT-cisplatin combination with key regulators of
cell cycle
We assessed the expression of the cell cycle regulators
P27 (kip1) and p21 in order to understand their role in
causing antagonistic or synergistic effects of BT and cis-
platin combination. Figure 4c and d show that BT and
cisplatin both enhanced expression of P27 (kip1) and
p21 when used alone. When cisplatin and BT were used
in combination, the expression of P27 and P21 was re-
duced in cisplatin-sensitive cell lines (A2780 and
IGROV-1) and enhanced in cisplatin-resistant cell lines


































































Fig. 3 Apoptotic effects of BT-cisplatin combination on isogenic pairs of ovarian cancer cell lines. Representative images of Hoechst 33258
staining of A2780 and A2780-CDDP (a) or IGROV and IGROV-1-CDDP (c) cells treated with BT and/or cisplatin as indicated. Percent of
apoptosis in terms of DNA fragmentation (quantified via TUNEL assay) are shown for A2780 and A2780-CDDP (b) or IGROV and IGROV-1-
CDDP (d) cells treated with BT or cisplatin alone or in combination. Data were expressed as means ± SD of duplicate experiments. Comparisons
between cisplatin alone treated and combination treated for each cell line were performed using Student’s t–test. Asterisks (*) indicate p < 0.05
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cisplatin or BT treatments alone. These results are con-
sistent with the cytotoxicity data, where combination
treatment potentiated cytotoxicity in cisplatin-resistant
cell lines and attenuated it in cisplatin-sensitive cell
lines.
BT potentiates cisplatin-induced apoptosis by increasing
ROS generation in cisplatin-resistant cell lines whereas it
reduces ROS in cisplatin-sensitive cell lines
We measured ROS levels to examine whether ROS are
involved in the synergistic/antagonistic interaction be-
tween cisplatin and BT. As shown in Fig. 5a and b, treat-
ment with BT or cisplatin alone lead to an increase in
ROS generation evidenced by a shift in fluorescence
peak (consistent with previous studies). Compared to
BT, cisplatin caused greater generation of ROS in most
of the cell lines. Our results further show that combin-
ational treatment with cisplatin and BT generated more
ROS relative to either of the drugs alone in cisplatin-
resistant cell lines whereas it decreased ROS generation
in cisplatin-sensitive cell lines. These results imply sig-
nificance of ROS in the cytotoxic effects of BT-cisplatin
combination. In order to confirm the role of ROS gener-
ation in antagonistic or synergistic interactions between
BT and cisplatin, we tested cell viability in the presence
or absence of the antioxidant ascorbic acid (AA). As
shown in Fig. 5c and d, combinational treatment with
cisplatin and BT in the presence of 1 mM AA restored
only 10–13% viability in cisplatin-sensitive cell lines
A2780 and IGROV-1. Interestingly, cisplatin-resistant
Fig. 4 Assessment of apoptosis induced by BT-cisplatin combination on ovarian cancer cell lines. The effect of BT-cisplatin combination
on caspase 3/7 activity was measured in A2780 and A2780-CDDP (a) or IGROV-1 and IGROV-1-CDDP (b) cells treated with BT or cisplatin
alone or in combination. Vehicle-treated cells were considered as control against which treated cells were compared. Data were expressed
as means ± SD of triplicate experiments. Comparisons between cisplatin alone-treated and combination-treated for each cell line were
performed using Student’s t–test. Asterisks (*) indicate p < 0.05. c and d Effect of BT/cisplatin combinations on Pro-apoptotic (cPARP), anti-
apoptotic (XIAP, bcl-2, bcl-xL) and cell cycle regulatory markers were assessed. Analysis of the expression of proteins in the lysates of
treated and untreated A2780 and A2780-CDDP (c) or IGROV-1 and IGROV-1-CDDP (d) cells was carried out by PAGE and western blot analysis. The blots
were probed with the respective primary antibodies. As an internal standard for equal loading, blots were probed with an anti-β-actin antibody
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variants displayed greater restoration of cell viability
(75 and 85% viability restoration in A2780-CDDP and
IGROV-1-CDDP, respectively). Treatment with 1 mM
AA did not cause any loss in cell viability in any of
the cell lines. These results implicate ROS-mediated
cytotoxicity in cisplatin-resistant cell lines when
treated with cisplatin and BT in combination. Lack of
significant restoration of cell viability in cisplatin-
sensitive cell lines implicates minimal contribution of
ROS upon combination treatment.
Fig. 5 Assessment of intracellular ROS and antioxidant effect on ovarian cancer celles treated with BT cisplatin combination. Flow cytometry
detection of intracellular ROS in A2780 and A2780-CDDP (a) or IGROV-1 and IGROV-1-CDDP (b) cells treated with BT or cisplatin alone or
in combination. Data are presented as relative-fluorescence intensities in a 2-dimensional FACS profile (standardized gating, 20,000 events).
Enhanced ROS generation is shown by shift in peaks. All experiments were performed in triplicate. c and d show the effect of the anti-
oxidant ascorbic acid on the viability (via PrestoBlue) of A2780 and A2780-CDDP (c) or IGROV-1 and IGROV-1-CDDP (d) cells treated with
BT or cisplatin alone or in combination. Control (untreated) cells were considered as 100% viable against which treated cells were compared. The
results represent % viability recovery when compared with 100 μM BT-treated cells. Data were expressed as means ± SD of triplicate experiments.
Comparisons between BT-cisplatin-treated in presence of ascorbic acid vs. combination-treated in the absence of ascorbic acid for each cell line were
performed using Student’s t–test. Asterisks (*) indicate p < 0.05
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Effect of BT-cisplatin combination on ATX
ATX inhibition was considered major mechanism of ac-
tion of BT. In order to determine if ATX inhibition po-
tential of BT has any contribution to the synergy
observed in cisplatin-resistant cell lines, we assessed the
ATX levels in cell lysates treated with either of the drugs
alone or in combination. As shown in Fig. 6a, no signifi-
cant changes in ATX were observed when A2780 or
A2780-CDDP cells were treated with either 12.5 μM BT
or 12.5 μM cisplatin alone. No significant difference was
seen when treated with BT-cisplatin combination also.
Figure 6b shows that 12.5 μM cisplatin did not cause
significant changes in ATX levels in either IGROV-1 or
IGROV1-CDDP cell lines (94 ± 3 and 92 ± 5%, respect-
ively). In contrast, treatment with 50 μM BT caused a
significant decrease in ATX in both cell lines (65 and
68% respectively). However, when added in combination
with cisplatin, no significant differences in ATX levels
were observed as compared to cisplatin alone (89 ± 5
and 88 ± 5%, respectively). These results confirm lack of
ATX involvement in drug interactions effects.
Discussion
Treatment with of ovarian cancer with a single antican-
cer agent often cannot provide a satisfactory therapeutic
effect in recurrent patients due to drug resistance and
dose-limiting side effects [30]. Therefore, it is essential
to find novel compounds/drugs that enhance the thera-
peutic efficiency of cisplatin, allowing for the use of
lower doses and therefore reducing its toxic side effects.
In this study we evaluated BT - cisplatin combination as
a novel treatment for ovarian cancer.
Previously, we showed that BT exerts cytotoxic effects
on a panel of ovarian cancer cell lines regardless of their
cisplatin sensitivities. BT was shown to induce apoptosis
both in vitro and in vivo [26, 27]. Our in vitro studies
suggested that BT’s mechanism(s) of action involve cell
cycle regulation, ROS generation, NF-κB inhibition and
ATX inhibition. In cisplatin-resistant cell lines, ROS
generation seems to be the major mechanism of BT
cytotoxicity [26]. Additionally, our recent in vivo study
showed that pharmaceutical grade BT was well tolerated
at relatively high concentrations without any toxic side
effects although an anti-tumor effect was not observed
at the doses tested [27]. Any drug that is known to cause
cell cycle mediated apoptosis, ROS generation or NF-κB
inhibition without any toxic effects is considered an ideal
candidate for combination with cisplatin for treatment
of ovarian cancer. Consequently, we chose BT to be
tested in combination with standard chemotherapeutic
agent(s) such as cisplatin and paclitaxel.
Combination chemotherapy has been in practice for
cancer treatments for many decades. The principle
underlying this approach so far has been to administer
each drug at their maximum tolerated dose (MTD) to
achieve maximum therapeutic efficiency. However, clin-
ical data suggested that this approach failed to exploit
the full potential of many therapeutic drugs used in
combinations and may have resulted in multidrug resist-
ance in tumor cells. The major reason for such a
phenomenon is exposure of tumor cells to drugs at an-
tagonistic ratios or concentrations. The nature of the in-
teractions (synergism or antagonism) of anticancer agent
combinations against tumor cells in vitro depends on
the concentrations of the individual drugs. Ratiometric
dosing is an approach to develop drug combinations
based on drug ratio–dependent synergy. It is essential to
determine optimal drug concentrations/ratios to obtain
Fig. 6 Effect of BT-cisplatin combination on ATX secretion in ovarian cancer cell lines. A2780 and A2780-CDDP (a) or IGROV-1 and IGROV-1-CDDP
(b) cells were treated with drugs either alone or in combination and ATX was measured from culture media (via a colorimetric assay). The percent
of ATX inhibition of treated cells was calculated using untreated cells as reference. Data were expressed as means ± SD of triplicate experiments.
Comparisons between cisplatin alone-treated and combination-treated for each cell line were performed using Student’s t–test. Asterisks (*)
indicate p < 0.05
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synergy so as to prevent the exposure of cells to antag-
onistic ratios. In our study, we employed both constant
and non-constant drugs ratios to understand the nature
of interactions between our two chosen drugs. BT and
cisplatin combinations were evaluated systematically for
concentration-dependent interactions in in vitro using
the isogenic ovarian cancer cell lines pairs A2780 (cis-
platin-sensitive) / A2780-CDDP (cisplatin-resistant) and
IGROV-1 (cisplatin-sensitive) / IGROV-1CDDP (cis-
platin-resistant). This study shows the differential re-
sponse of cisplatin-sensitive and cisplatin-resistant cell
lines to BT/cisplatin combination treatment. In
cisplatin-sensitive cell lines, BT/cisplatin combination
was antagonistic at most drug concentrations; however
the use of lower concentrations of BT and cisplatin re-
sulted in synergy. In contrast, when tested on cisplatin-
resistant cell lines, these agents were synergistic at most
of the ratios/concentrations. Our results show that syn-
ergy is highly dependent on the concentration of the
drugs used. Optimal response was observed when BT
and cisplatin were combined at lower concentrations in
a non-constant ratio. With regard to sequence of drugs
applied, simultaneous treatment with BT and cisplatin
appears to be a better option as compared to pretreat-
ment with BT followed by cisplatin treatment. These
results support the fact that BT sensitizes cisplatin-
resistant cells to respond better to cisplatin treatment.
As reported by many, drug ratios identified as antag-
onistic in vitro provide inferior therapeutic activity in
vivo compared with a synergistic drug ratio. Hence, it is
very important to determine optimal drug ratios and
then translate in vitro information on drug ratio-
dependent synergy to in vivo efficacy using various drug
delivery technologies. Combination drug delivery sys-
tems such as polymeric nanoparticles, dendrimers, lipo-
somes, and water-soluble polymer-drug conjugates can
be used to obtain synergistic anticancer effects while re-
ducing concentration-related toxicity of the individual
drugs [31, 32].
In addition to determining an optimal drug combin-
ation, the aim of this study was to investigate mo-
lecular mechanism(s) of action of BT/cisplatin
combination in ovarian cancer cells in vitro. Oxidative
stress and apoptosis are often the main factors con-
tributing to the anticancer effects of drugs that target
DNA [33, 34]. Since both BT and cisplatin are known
to induce DNA damage, we evaluated induction of
apoptosis, ROS generation, and expression of key
apoptotic and cell cycle modulators as possible mech-
anisms of action for BT-cisplatin combination. The
fact that BT has been reported to inhibit ATX activity
prompted us to determine the effect of BT/cisplatin
combination on ATX levels as well [26, 35, 36]. Sur-
prisingly, when BT was added in combination with
cisplatin, no significant differences in ATX levels were
observed for any paired cell lines (IGROV-1 and
A2780). We surmise that ATX inhibition does not
play a critical role in the mechanism of action of the
BT/cisplatin combination in these cell lines.
There is a consensus pointing to apoptosis as the prin-
cipal mechanism by which chemotherapy agents induce
cancer cell death. The majority of anticancer drugs
induce apoptosis via the intrinsic (mitochondrial - cyto-
chrome c/Apaf-1/caspase-9) pathway [37, 38]. Mito-
chondria are known to be both a source and a target of
ROS. Disruption of mitochondrial potential can lead to
oxidation of mitochondrial pores by ROS, resulting in
release of cytochrome C into the cytosol [39]. The for-
mation of an apoptosome containing cytochrome C,
apoptotic protease activating factor-1 (Apaf-1) and dATP
is followed by procaspase-9 recruitment and activation.
Subsequently, Caspase-9 activates caspases −3 and −7
which execute the final steps of apoptosis. Consistent
with previous reports on BT and cisplatin [11, 26, 27],
our study shows that BT and cisplatin, when used alone,
induce DNA fragmentation indicative of apoptosis. Fur-
thermore, in cisplatin-sensitive variants, cells treated
with individual drugs alone displayed higher degrees of
apoptosis as compared to BT-cisplatin combination. In
contrast, cisplatin-resistant variants treated with BT-
cisplatin combination exhibited more apoptosis than
those treated with either cisplatin or BT alone. In order
to confirm the results obtained with DNA fragmentation
assays, we also measured other markers of apoptosis.
BT/cisplatin combination treatment reduced caspases
activity and cleaved PARP in cisplatin-sensitive cell lines.
In contrast, increased caspases 3/7 activity and cleaved
PARP was observed in cisplatin-resistant variants of
these isogenic cell line pairs treated with both drugs in
combination as compared to when treated with either of
the drugs alone. The nature of drug interactions depends
on the extent of apoptosis that occurs when the drugs
are used in combination. Synergistic interaction en-
hanced apoptosis whereas antagonistic interactions re-
duced extent of apoptosis.
Several compounds have been shown to alleviate
cisplatin-induced nephrotoxicity through the transla-
tional regulation of Bcl-2 [40, 41]. Bcl-2 overexpression
in conjunction with p53 has been found in fresh ovarian
tissue biopsies [42]. Bcl-2 has been reported to protect
ovarian cancer cells from drug-induced apoptosis, con-
tributing to chemo-resistance [42, 43]. Inhibition of bcl-
xL may increase sensitivity to chemotherapy agents such
as carboplatin [44]. In this context, we also assessed the
expression of pro-survival factors such as XIAP, bcl-2
and Bcl-xL. We found that in cisplatin-sensitive cell
lines, BT/cisplatin combination reduced cisplatin-
induced apoptotic effects as increased expressions of
Ayyagari et al. BMC Cancer  (2017) 17:49 Page 12 of 15
XIAP, bcl-2 and bcl-xL was observed. In contrast,
cisplatin-resistant cell lines showed significant down
regulation of XIAP, bcl-2, bcl-xL when treated with BT/
cisplatin combination as compared to either agent alone,
thus resulting in greater apoptosis/cytotoxicity. These
observations implicate BT/cisplatin combination may be
a useful approach in treating cisplatin-resistant ovarian
cancers.
ROS are byproducts of normal cellular metabolism
which play a crucial role in cell regulation and signal
transduction [45]. Many studies have shown that cancer
cells display elevated ROS levels compared to non-
cancerous cells; thus, further ROS increase would make
cancer cells more susceptible to oxidative damage
(reviewed in [46]). Indeed, a number of common chemo-
therapeutic drugs including daunorubicin, cyclophospha-
mide, Taxol and cisplatin have been proposed to induce
apoptosis through the generation of an excess amount of
ROS [47–49]. However, prolonged exposure to cisplatin
may reduce cellular levels of ROS resulting in chemo-
resistance. Enhanced elevation of cellular ROS level by
an exogenous ROS source in combination with cisplatin
may re-sensitize drug-resistant cancer cells [50]. We
used this approach to augment efficiency of cisplatin in
cisplatin-resistant cells by combining cisplatin with BT.
Previously, generation of ROS has been established as
one of the underlying mechanisms of both BT and cis-
platin cytotoxic activity [26, 51, 52]. Consistent with
these previous reports, our study shows that treatment
with either BT or cisplatin generated ROS, although
ROS concentration was greater in cisplatin treated cells.
Combination of cisplatin with BT further enhanced ROS
production. Blocking ROS production by addition of
antioxidant ascorbic acid showed a complete remission
of cell death in cisplatin-resistant cells treated with BT/
cisplatin suggesting that ROS production is the major
mechanism of cell death for BT-cisplatin combination,
thus overcoming cisplatin resistance. Our results show
that BT/cisplatin combination potentiated cisplatin in-
duced cytotoxicity by augmenting ROS accumulation
and consequently activated pro-apoptosis pathways, es-
pecially in cisplatin-resistant cell lines.
Platinum derivatives have previously been shown to
increase the expression of important cell cycle regulatory
proteins such as p27 Kip1 and p21 Waf1/Cip1, leading
to cell cycle inhibition [53, 54]. Similarly, BT was shown
to cause increased expression of proteins P27 (kip1) and
p21 in ovarian cancer cell lines in in vitro [26]. We
assessed the expression of P27 (kip1) and p21 in order
to understand the role of these cell cycle regulators in
causing antagonism or synergy of cisplatin and BT com-
bination. Our results suggest that BT reduced the mag-
nitude of cisplatin-induced cell cycle arrest by inhibiting
P27 (kip1) and p21 expression in cisplatin-sensitive cell
lines whereas it enhanced their expression in cisplatin-
resistant cell lines. With P27 (kip1) and p21 being key
inhibitors of cell cycle, our results are consistent with
the cytotoxicity data where BT-cisplatin combination
treatment potentiated and attenuated cytotoxicity in
cisplatin-resistant and cisplatin-sensitive cell lines,
respectively.
It is known that the major drawback of current cancer
chemotherapy treatments is that the use of different
drugs at high doses results in undesired toxicity, drug re-
sistance and lack of expected efficacy (possibly as a con-
sequence of antagonistic interactions between the drugs
used). As reported in this study, drugs can be synergistic
at certain ratios and antagonistic at other ratios implying
the need to administer them at optimal doses. Therefore,
there is a need to optimize drug ratios for every combin-
ation of drug used. Our results show that the use of cis-
platin and BT at lower doses enhanced the efficacy of
both drugs in most ovarian cancer cell lines tested.
When used in combination with BT, cisplatin can be ad-
ministered at lower doses, eliminating undesired side ef-
fects without compromising its efficacy. In this context,
our study provides very significant systematic evaluation
of BT-cisplatin interactions for possible application in
drug/cisplatin resistance ovarian cancer scenarios.
Conclusions
Our results show that BT and cisplatin can be synergistic
at certain ratios and antagonistic at other ratios implying
the need to administer them at optimal doses. When
used at optimal concentrations, BT/cisplatin combin-
ation potentiated cisplatin cytotoxicity by increasing the
accumulation of ROS and consequently activating pro-
apoptotic pathways in cisplatin-resistant cell lines. Our
results suggest that repurposing of BT to be used in
combination with cisplatin represents an attractive and
innovative approach to enhance/restore chemosensitivity
of ovarian cancer to cisplatin. Further in vivo experi-
ments may further contribute to our understanding and
confirm the therapeutic potential of BT for patients with
ovarian cancer.
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